Lamotrigine concentrations in human serum, brain tissue, and tumor tissue

Epilepsia

Volumn 40, Issue 1, 1999, Pages 68-73

  Meyer, Frank P ^a,c   Banditt, Peter ^a   Schubert, Adrian ^b   Schöche, Jochen ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Clinic of Neurosurgery   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Brain tissue; Lamotrigine; Patients; Protein binding

Indexed keywords

LAMOTRIGINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG TUMOR LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROSURGERY; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; TISSUE DISTRIBUTION; TRIAZINES; ULTRAFILTRATION;

EID: 0032920526     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb01990.x     Document Type: Article

References (26)

1. Lees G, Leach MJ. Studies on the mechanism of action of the novel anti-convulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993;612:190-9.
2. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7.
3. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
4. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
5. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
6. Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
7. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
8. Reunanen M, Dam M, Yuen AWC. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
9. Steiner TJ, Silveira C, Yuen AWC. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [Abstract], Epilepsia 1994;35(suppl 7):61.
10. Remmel RP, Sinz MW, Graves NM, Ritter FJ. Lamotrigine and lamotrigine-N-glucuronide concentrations in human blood and brain tissue [Abstract]. Seizure 1992;1(suppl A):P7/34.
11. Jürgens, U. Extrelut bei der HPLC-Analyse von Antiepileptika. Kontakte 1988;1:41-53.
12. Scholtan W. Bestimmungsmethoden und Gesetzmäβigkeiten der Serumproteinbindung von Arzneimitteln. Arzneimittelforschung 1978;28:1037-47.
13. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:152-76.
14. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
15. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
16. Binnie CD, Emde Boas WV, Kastelein-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW 430 C) in persons with epilepsy. Epilepsia 1986:27:248-54.
17. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
18. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
19. Mikati MA, Schachter SC, Schomer DL, et al. Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989;12:312-21.
20. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32(suppl 2):S9-12.
21. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
22. Blankenhorn V, Hoffmann HG, Polatschek B. Akute Intoxikation mit dem neuen Antiepileptikum Lamotrigin nach Suizidversuch. In: Scheffner D, ed. Epilepsie 91. Reinbek: Enihorn, 1992;473-5.
23. Eriksson AS, Hoppu K, Nergårdh A, Boreus L. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996;37:769-73.
24. Vanzelle-Kervroëdan F, Rey E. Cieuta C. et al. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996;41:325-30.
25. Kirsch W, Hoensch H, Ohnhaus EE, Janisch HD. Ranitidin-Nifedipin-Interaktion. Dtsch Med Wochenschr 1984;109:1223.
26. Meyer FP. Beitrag zum Problem der Wechselwirkungen zwischen Proteinen und Sulfanilamiden. Acta Biol Med Germ 1972;28:21-5.